Table 1 Characteristics and clinical presentation of COVID-19-infected PH cases
From: Impact and predictors of outcome of COVID-19 in pulmonary hypertension patients
Variable | Frequency (21) | % |
|---|---|---|
Gender | ||
 Male | 6 | 28.6 |
 Female | 15 | 71.4 |
Comorbidities | 7 | 33.3 |
 Chronic liver disease | 3 | 14.3 |
 Diabetes mellitus | 1 | 4.8 |
 Hypothyroidism | 1 | 4.8 |
 Cardiac | 1 | 4.8 |
 Hypertension | 1 | 4.8 |
Complication Acute renal failure | 2 | 9.5 |
Pulmonary hypertension diagnosis | ||
 Idiopathic PAH | 6 | 28.6 |
 Schistosomiasis-PH | 4 | 19.0 |
 CTEPH | 4 | 19.0 |
 CTD-PH | 3 | 14.3 |
 Porto-PH | 2 | 9.5 |
 Drug-induced PH | 1 | 4.8 |
 CHD (ES) | 1 | 4.8 |
PPH-specific treatment regimen | ||
 Dual therapy | 14 | 66.7 |
 Triple therapy | 3 | 14.3 |
 CCB | 2 | 9.5 |
 No | 2 | 9.5 |
Immunosuppressive treatment | 7 | 33.3 |
 One drug (prednisolone) | 4 | 19.2 |
 Two drugs (prednisolone with another drug) | 2 | 9.5 |
 Three drugs (prednisolone with other drugs) | 1 | 4.8 |
Anticoagulants | ||
 Yes | 4 | 19.0 |
 No | 17 | 81.0 |
Symptoms | ||
 Fever | 12 | 57.1 |
 Dyspnea | 12 | 57.1 |
 Dry cough | 13 | 61.9 |
 Fatigue | 4 | 19.0 |
 Headache | 3 | 14.3 |
 Chest pain | 1 | 4.8 |
  Hypoxia | 6 | 28.6 |
  Hospitalization | 7 | 33.3 |
Severity | ||
 Mild | 8 | 38.1 |
 Moderate | 7 | 33.3 |
 Severe | 2 | 9.5 |
 Critical | 4 | 19.0 |
Outcome | ||
 Cure | 18 | 85.7 |
 Death | 3 | 14.3 |